DOJ sues former laboratory executives over $13.7 million in allegedly unnecessary Medicare testing
Oct 11, 2026 edition · GC-2026-0104 · Published 2026-10-11 · Version 4 · Pending litigation
DOJ’s civil complaint alleges former Capstone executives generated $13.7 million in unnecessary Medicare testing through religious events and senior communities. The complaint and related criminal charges are pending in the cited announcement; separate settlements with other parties are not judgments against these executives.
What happened
DOJ’s September 17 release describes a False Claims Act complaint against former Capstone Diagnostics executives Jay Johnson and Austin Whiles and associated entities. The complaint alleges that genetic testing at church health fairs and religious conferences was generated without valid treating-provider orders. It also alleges that medically unnecessary respiratory pathogen panels were added to COVID-19 testing for senior living communities. Across the two alleged schemes, Medicare paid approximately $13.7 million from 2019 through 2021. This amount is alleged program payment, not an awarded civil judgment.
The alleged mechanisms included copied physician signatures, broad standing orders, standardized diagnosis codes, sales staff entering orders and remuneration tied to testing volume. DOJ separately reported settlements with Capstone and its owner for $14.3 million and with billing company VitalAxis for $300,479. Those resolutions concern the settling parties and do not establish liability against the former executives in the pending complaint. Johnson’s related criminal charges were also pending in the announcement. For readers, the practical distinction is between an alleged ordering-and-marketing pattern that warrants control testing and a judicial determination that has not been reported.
Scope and timing
- Authority status
- Pending litigation
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, Georgia
Why it matters
The complaint identifies laboratory controls that can fail together: treating-provider authorization, standing-order limits, diagnosis specificity, sales access to ordering workflows, medical necessity, and remuneration tied to volume.
Recommended action
Sample genetic and respiratory panel claims for individualized treating-provider orders, valid signatures, patient-specific diagnoses, medical necessity, and marketer compensation. Remove sales access to clinical ordering functions and escalate copied or standing-order patterns.
Case details
- agencies
- U.S. Department of Justice, HHS Office of Inspector General, Federal Bureau of Investigation
- entities
- Jay Johnson, Austin Whiles, Associated entities identified in the complaint
- action Type
- Civil complaint
- event Date
- 2026-09-17
- alleged Conduct
- Alleged medically unnecessary genetic and respiratory panel testing generated through mass events, copied signatures, standing orders, standardized diagnoses, sales ordering, and kickbacks.
- resolution
- Complaint filed. Liability has not been determined.
Operational lessons
- Laboratory tests need individualized treating-provider orders.
- Sales personnel should not create clinical orders.
- Standing orders and copied signatures require focused monitoring.
- Marketer compensation must not reward federally reimbursed test volume.
Sources
- DOJ Sues Former Georgia Lab Execs for Defrauding Medicare by Targeting Faith-Based Communities and SeniorsOfficial · U.S. Attorney Office, Northern District of Georgia · 2026-09-17 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →